Developer docs
API playgroundTry for free, no card

Search company profiles

Lomond Therapeutics

Full company profile

uuid0000vmp

Namestring
Lomond Therapeutics
Legal namestring
Lomond Therapeutics Holdings, Inc.
Websiteurl
lomondther.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies. The company's pipeline is anchored by three differentiated programs: Lomonitinib, a pan-FLT3/IRAK4 inhibitor in Phase 1b trials in Australia and the United States for relapsed/refractory AML driven by FLT3 mutations; Lonitoclax, a next-generation BCL-2 inhibitor with best-in-class selectivity for BCL-2 over BCL-XL and no CYP3A4 liability, in Phase 1 trials for CLL, SLL, low-grade lymphomas, and now AML; and a menin inhibitor program licensed from Bala Therapeutics in pre-clinical/IND-enabling work for NPM-1 and MLL-rearranged AML. Lomond is a development-stage spin-out of Eilean Therapeutics LLC and leverages Eilean's proprietary hybrid AI platform, Expert Systems Inc., which combines proprietary chem-bio data, knowledge, and tools for multi-target, multi-property optimization and rational compound design.

The company employs 11–50 people and is incorporated in Delaware (Lomond Therapeutics Holdings, Inc.) following its November 2024 reverse merger with Venetian-1 Acquisition Corp, a Montrose Capital SPAC. Lomond is pre-revenue; commercialization upon regulatory approval will rely on traditional pharmaceutical distribution channels including specialty pharmacies, hospital buying groups, and oncology specialty distributors. Capital structure is anchored by co-founders and lead investors OrbiMed and Torrey Pines Investment, with Deerfield Management leading the $44 million private placement closed alongside the reverse merger, and Yosemite Management and Qatar Investment Authority joining in a $20 million follow-on in March 2025, bringing cumulative funding to approximately $64 million. Scientific leadership is anchored by co-founder Dr. John C. Byrd (Chairman of the Scientific Advisory Board and Interim CMO) and the University of Cincinnati Leukemia Drug Development Laboratory, with CEO Iain Dukes (also an OrbiMed Venture Partner) leading the management team alongside CSO Amy Burd and CDO Brian Ledwith.

Short descriptiontext

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies, with three programs (lomonitinib, lonitoclax, menin inhibitors) addressing FLT3-mutated AML, BCL-2-driven CLL/AML, and NPM-1/MLL-rearranged AML.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule oncology, hematologic cancer therapeutics, clinical-stage biotechnology, targeted cancer therapy, drug discovery platform
Industry3 codes
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Hematologic Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company. Expected to generate revenue through commercialization of novel small molecule therapeutics for hematologic malignancies upon regulatory approval.

lomondther.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies. Its pipeline comprises three differentiated programs: Lomonitinib (a pan-FLT3/IRAK4 inhibitor in Phase 1b for AML), Lonitoclax (a next-generation BCL-2 inhibitor in Phase 1 for CLL and AML), and a Menin inhibitor program (preclinical) for NPM-1 and MLL-rearranged AML. The company leverages a proprietary hybrid AI drug discovery platform to accelerate rational small molecule design.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Lonitoclax demonstrated no significant safety signals at exposures where robust BCL-2 inhibition was achieved in Phase 1 healthy volunteer studies
+3 more records
Product overview1 text field

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of small molecule oncology drug candidates targeting escape mutations in hematologic malignancies. The company's portfolio consists of three differentiated programs: Lomonitinib (pan-FLT3/IRAK4 inhibitor for AML in Phase 1b), Lonitoclax (BCL-2 inhibitor for CLL and AML in Phase 1), and Menin Inhibitors (for NPM-1 and MLL-rearranged AML in discovery). The company leverages a proprietary hybrid AI platform to accelerate rational drug design and development of best-in-class and first-in-class therapies.

Product and service3 records
1Lomonitinib
CategorySmall Molecule Oncology Drug Candidate
Description

A novel, highly potent and selective pan-FLT3/IRAK4 inhibitor designed to block activity of all major known FLT3 resistance mutations (ITD, TKD, and other clinically relevant mutations) and IRAK4 simultaneously in acute myeloid leukemia. In Phase 1b clinical development in Australia and the United States for relapsed/refractory AML patients with FLT3 mutations.

2Lonitoclax
CategorySmall Molecule Oncology Drug Candidate
Description

A next-generation, oral once-daily BCL-2 inhibitor designed with a unique binding mode to improve selectivity for BCL-2 over BCL-XL, mitigate hematologic and immune toxicities seen with venetoclax, and avoid CYP3A4 drug-drug interactions. In Phase 1 clinical development for relapsed/refractory CLL, small lymphocytic lymphoma, select low-grade lymphomas, and AML.

3Menin Inhibitor Program
CategorySmall Molecule Oncology Drug Candidate
Description

A class of menin inhibitors licensed exclusively from Bala Therapeutics for the treatment of NPM-1 and MLL-rearranged acute myeloid leukemia. In discovery/IND-enabling stage with candidate selection expected in second half of 2025.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-04
Description

Lomond Therapeutics completed a reverse merger transaction with Venetian-1 Acquisition Corp (sponsored by Montrose Capital). Following the merger, Venetian-1 was renamed Lomond Therapeutics Holdings, Inc.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lomond Therapeutics is a spin-out/clinical-stage subsidiary of Eilean Therapeutics LLC, a precision oncology-focused discovery and development platform. The company leverages Eilean's proprietary hybrid AI platform, Expert Systems Inc., for drug discovery and development. Pre-clinical work was conducted by Eilean in collaboration with the Leukemia Drug Development Laboratory at the University of Cincinnati.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pre-clinical work for lonitoclax and lomonitinib was conducted in collaboration with the Leukemia Drug Development Laboratory at the University of Cincinnati, led by Dr. John C. Byrd and Dr. Erin Hertlein.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-driven computational drug discovery platform with oncology pipeline programs — comparable to Lomond's hybrid AI/Expert Systems discovery engine and emerging clinical-stage pipeline.

TypeDirect peer
Description

Clinical-stage biotech developing chromatin-based small molecule therapies for hematologic cancers including AML — directly comparable in target class, indication focus, and clinical maturity.

TypeDirect peer
Description

Clinical-stage oncology company developing menin inhibitors (ziftomenib) and a tipifarnib-based program for hematologic malignancies — directly comparable to Lomond's menin and FLT3 programs targeting similar genetically-defined AML populations.

TypeEmerging player
Description

Clinical-stage developer of targeted protein degraders using a computationally-enabled discovery platform — comparable to Lomond's stated protein degrader/molecular glue modality capabilities.

TypeDirect peer
Description

Clinical-stage developer of small molecule kinase inhibitors for hematologic cancers (luxeptinib, tuspetinib) — comparable pipeline scope, indication focus, and clinical-stage risk profile to Lomond.

TypeBroad incumbent
Description

Developer of venetoclax (Venclexta), the entrenched BCL-2 inhibitor Lomond's lonitoclax must differentiate against — also a likely strategic acquirer given portfolio fit.

TypeDirect peer
Description

Commercial-stage developer of revumenib (menin inhibitor, approved for KMT2A-rearranged AML) — directly competing in Lomond's menin inhibitor indication and representing the bar Lomond must beat.

TypeBroad incumbent
Description

Developer of gilteritinib (Xospata), the established FLT3 inhibitor for relapsed/refractory AML that Lomond's lomonitinib is designed to improve upon.

TypeEmerging player
Description

AI/ML-driven drug discovery company with pipeline across oncology and rare diseases — overlaps Lomond's hybrid AI platform approach to small molecule design.

TypeBroad incumbent
Description

Developer of quizartinib (Vanflyta), approved FLT3 inhibitor for newly diagnosed FLT3-ITD AML — incumbent Lomond must clinically differentiate against in pan-FLT3 AML.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lomond Therapeutics

Hematologic Oncology Therapeuticslomondther.com

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies, with three programs (lomonitinib, lonitoclax, menin inhibitors) addressing FLT3-mutated AML, BCL-2-driven CLL/AML, and NPM-1/MLL-rearranged AML.

What Lomond Therapeutics does

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies. The company's pipeline is anchored by three differentiated programs: Lomonitinib, a pan-FLT3/IRAK4 inhibitor in Phase 1b trials in Australia and the United States for relapsed/refractory AML driven by FLT3 mutations; Lonitoclax, a next-generation BCL-2 inhibitor with best-in-class selectivity for BCL-2 over BCL-XL and no CYP3A4 liability, in Phase 1 trials for CLL, SLL, low-grade lymphomas, and now AML; and a menin inhibitor program licensed from Bala Therapeutics in pre-clinical/IND-enabling work for NPM-1 and MLL-rearranged AML. Lomond is a development-stage spin-out of Eilean Therapeutics LLC and leverages Eilean's proprietary hybrid AI platform, Expert Systems Inc., which combines proprietary chem-bio data, knowledge, and tools for multi-target, multi-property optimization and rational compound design.

The company employs 11–50 people and is incorporated in Delaware (Lomond Therapeutics Holdings, Inc.) following its November 2024 reverse merger with Venetian-1 Acquisition Corp, a Montrose Capital SPAC. Lomond is pre-revenue; commercialization upon regulatory approval will rely on traditional pharmaceutical distribution channels including specialty pharmacies, hospital buying groups, and oncology specialty distributors. Capital structure is anchored by co-founders and lead investors OrbiMed and Torrey Pines Investment, with Deerfield Management leading the $44 million private placement closed alongside the reverse merger, and Yosemite Management and Qatar Investment Authority joining in a $20 million follow-on in March 2025, bringing cumulative funding to approximately $64 million. Scientific leadership is anchored by co-founder Dr. John C. Byrd (Chairman of the Scientific Advisory Board and Interim CMO) and the University of Cincinnati Leukemia Drug Development Laboratory, with CEO Iain Dukes (also an OrbiMed Venture Partner) leading the management team alongside CSO Amy Burd and CDO Brian Ledwith.

Lomond Therapeutics firmographics

Firmographics
Name
Lomond Therapeutics
Legal name
Lomond Therapeutics Holdings, Inc.
Website
https://lomondther.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies, with three programs (lomonitinib, lonitoclax, menin inhibitors) addressing FLT3-mutated AML, BCL-2-driven CLL/AML, and NPM-1/MLL-rearranged AML.
Ownership category
akta.pro rank

Lomond Therapeutics industry classification

Industry
Product category
Hematologic Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Small molecule oncology
  • Hematologic cancer therapeutics
  • Clinical-stage biotechnology
  • Targeted cancer therapy
  • Drug discovery platform

Where Lomond Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Lomond Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Expected to generate revenue through commercialization of novel small molecule therapeutics for hematologic malignancies upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Lomond Therapeutics product offering

Product offering

Core offering

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies. Its pipeline comprises three differentiated programs: Lomonitinib (a pan-FLT3/IRAK4 inhibitor in Phase 1b for AML), Lonitoclax (a next-generation BCL-2 inhibitor in Phase 1 for CLL and AML), and a Menin inhibitor program (preclinical) for NPM-1 and MLL-rearranged AML. The company leverages a proprietary hybrid AI drug discovery platform to accelerate rational small molecule design.

Product overview

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of small molecule oncology drug candidates targeting escape mutations in hematologic malignancies. The company's portfolio consists of three differentiated programs: Lomonitinib (pan-FLT3/IRAK4 inhibitor for AML in Phase 1b), Lonitoclax (BCL-2 inhibitor for CLL and AML in Phase 1), and Menin Inhibitors (for NPM-1 and MLL-rearranged AML in discovery). The company leverages a proprietary hybrid AI platform to accelerate rational drug design and development of best-in-class and first-in-class therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lomonitinib A novel, highly potent and selective pan-FLT3/IRAK4 inhibitor designed to block activity of all major known FLT3 resistance mutations (ITD, TKD, and other clinically relevant mutations) and IRAK4 simultaneously in acute myeloid leukemia. In Phase 1b clinical development in Australia and the United States for relapsed/refractory AML patients with FLT3 mutations.
  • Lonitoclax A next-generation, oral once-daily BCL-2 inhibitor designed with a unique binding mode to improve selectivity for BCL-2 over BCL-XL, mitigate hematologic and immune toxicities seen with venetoclax, and avoid CYP3A4 drug-drug interactions. In Phase 1 clinical development for relapsed/refractory CLL, small lymphocytic lymphoma, select low-grade lymphomas, and AML.
  • Menin Inhibitor Program A class of menin inhibitors licensed exclusively from Bala Therapeutics for the treatment of NPM-1 and MLL-rearranged acute myeloid leukemia. In discovery/IND-enabling stage with candidate selection expected in second half of 2025.

Quantifiable outcome

  • Lonitoclax demonstrated no significant safety signals at exposures where robust BCL-2 inhibition was achieved in Phase 1 healthy volunteer studies
  • +3 more outcomes

Companies that use Lomond Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Lomond Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Lomond Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Venetian-1 Acquisition CorpcoreStrategic or Co-development Partner · 4 November 2024Lomond Therapeutics completed a reverse merger transaction with Venetian-1 Acquisition Corp (sponsored by Montrose Capital). Following the merger, Venetian-1 was renamed Lomond Therapeutics Holdings, Inc.
  • Eilean Therapeutics LLCcoreStrategic or Co-development PartnerLomond Therapeutics is a spin-out/clinical-stage subsidiary of Eilean Therapeutics LLC, a precision oncology-focused discovery and development platform. The company leverages Eilean's proprietary hybrid AI platform, Expert Systems Inc., for drug discovery and development. Pre-clinical work was conducted by Eilean in collaboration with the Leukemia Drug Development Laboratory at the University of Cincinnati.
  • University of Cincinnati (Leukemia Drug Development Laboratory)coreStrategic or Co-development PartnerPre-clinical work for lonitoclax and lomonitinib was conducted in collaboration with the Leukemia Drug Development Laboratory at the University of Cincinnati, led by Dr. John C. Byrd and Dr. Erin Hertlein.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Lomond Therapeutics competitors and assessment

Company assessment

Emerging players

  • Schrödinger, Inc. AI-driven computational drug discovery platform with oncology pipeline programs — comparable to Lomond's hybrid AI/Expert Systems discovery engine and emerging clinical-stage pipeline.
  • Kymera Therapeutics: Clinical-stage developer of targeted protein degraders using a computationally-enabled discovery platform — comparable to Lomond's stated protein degrader/molecular glue modality capabilities.
  • Recursion Pharmaceuticals: AI/ML-driven drug discovery company with pipeline across oncology and rare diseases — overlaps Lomond's hybrid AI platform approach to small molecule design.

Direct peers

  • Foghorn Therapeutics: Clinical-stage biotech developing chromatin-based small molecule therapies for hematologic cancers including AML — directly comparable in target class, indication focus, and clinical maturity.
  • Kura Oncology: Clinical-stage oncology company developing menin inhibitors (ziftomenib) and a tipifarnib-based program for hematologic malignancies — directly comparable to Lomond's menin and FLT3 programs targeting similar genetically-defined AML populations.
  • Aptose Biosciences: Clinical-stage developer of small molecule kinase inhibitors for hematologic cancers (luxeptinib, tuspetinib) — comparable pipeline scope, indication focus, and clinical-stage risk profile to Lomond.
  • Syndax Pharmaceuticals: Commercial-stage developer of revumenib (menin inhibitor, approved for KMT2A-rearranged AML) — directly competing in Lomond's menin inhibitor indication and representing the bar Lomond must beat.

Broad incumbents

  • AbbVie: Developer of venetoclax (Venclexta), the entrenched BCL-2 inhibitor Lomond's lonitoclax must differentiate against — also a likely strategic acquirer given portfolio fit.
  • Astellas Pharma: Developer of gilteritinib (Xospata), the established FLT3 inhibitor for relapsed/refractory AML that Lomond's lomonitinib is designed to improve upon.
  • Daiichi Sankyo: Developer of quizartinib (Vanflyta), approved FLT3 inhibitor for newly diagnosed FLT3-ITD AML — incumbent Lomond must clinically differentiate against in pan-FLT3 AML.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lomond Therapeutics social profiles

Digital presence

Lomond Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lomond Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Lomond Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lomond Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lomond Therapeutics

What does Lomond Therapeutics do?

Lomond Therapeutics is a clinical-stage biopharmaceutical company developing best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies. Its pipeline comprises three differentiated programs: Lomonitinib (a pan-FLT3/IRAK4 inhibitor in Phase 1b for AML), Lonitoclax (a next-generation BCL-2 inhibitor in Phase 1 for CLL and AML), and a Menin inhibitor program (preclinical) for NPM-1 and MLL-rearranged AML. The company leverages a proprietary hybrid AI drug discovery platform to accelerate rational small molecule design.

Is Lomond Therapeutics a public or private company?

Lomond Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lomond Therapeutics founded?

Lomond Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Lomond Therapeutics based?

Lomond Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Lomond Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Lomond Therapeutics's main competitors?

Emerging players on record are Schrödinger, Inc., Kymera Therapeutics and Recursion Pharmaceuticals. Direct peers are Foghorn Therapeutics, Kura Oncology, Aptose Biosciences and Syndax Pharmaceuticals. Broad incumbents are AbbVie, Astellas Pharma and Daiichi Sankyo.

Does Lomond Therapeutics have an API?

No public API is recorded for Lomond Therapeutics.

What industry is Lomond Therapeutics in?

Lomond Therapeutics's product category is Hematologic Oncology Therapeutics. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLOMOND THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR LONITOCLAX, A SELECTIVE BCL2 INHIBITOR WITH LIMITED IMMUNE SUPPRESSION AND IMPROVED SAFETY COMPARED TO VENETOCLAX AND VENETOCLAXLomond Therapeutics received FDA IND clearance to begin a Phase 1 multicenter study evaluating lonitoclax in combination with azacitidine for relapsed/refractory acute myeloid leukemia, marking the company's third U.S. IND. The trial will include dose escalation and expansion phases with up to 60 participants and is planned to initiate in Q3 2025 across multiple investigative sites. Lonitoclax is a BCL2 inhibitor designed with limited immune suppression and improved safety over venetoclax, having demonstrated no significant safety signals in completed healthy volunteer studies.LomondtherLomond Therapeutics Completes Second and Third Closings and adds Two New Investors — Lomond TherapeuticsLomond Therapeutics completed second and third closings, adding Yosemite Management and QIA Investments, and raised $20 million in private placement financing. The funds will advance its FLT3 inhibitor lomonitinib, BCL-2 inhibitor lonitoclax, and a menin inhibitor through clinical development.PR NewswireLomond Therapeutics Completes Second and Third Closings and adds Two New InvestorsLomond Therapeutics completed second and third closings, adding Yosemite Management and QIA Investments, and raised an additional $20 million in private placement financing. The funds will advance its FLT3 inhibitor lomonitinib, BCL-2 inhibitor lonitoclax, and a menin inhibitor through clinical development.YahooLomond Therapeutics Completes Second and Third Closings and adds Two New InvestorsLomond Therapeutics completed second and third closings, adding Yosemite Capital and QIA Investments, and raised $20 million in private placement financing. The funds will advance its FLT3 inhibitor lomonitinib, BCL-2 inhibitor lonitoclax, and a menin inhibitor through clinical development.SecSEC FORM DLomond Therapeutics Holdings, Inc. filed a Notice of Exempt Offering of Securities with the SEC, indicating a total offering amount of $43.9 million. The issuance of shares is part of a business combination transaction following a reverse merger with Lomond Operating Co., with initial sales to accredited investors.